Share
.webp)
.webp)
.webp)
.webp)
Marcel Reichen
Ratio Therapeutics Inc. (Ratio), a pharmaceutical company advancing next-generation radiopharmaceuticals for cancer treatment and monitoring, has appointed Marcel Reichen, Ph.D., MBA, as its new Chief Strategy Officer.
This strategic move underscores Ratio’s commitment to expanding its leadership team with seasoned experts who can guide long-term growth and strengthen the company’s position in the rapidly evolving radioligand therapy (RLT) landscape.
Dr. Reichen brings more than a decade of international experience across the pharmaceutical and RLT sectors, with a strong record of value creation, strategic leadership, and cross-functional execution. Before joining Ratio, he served as Executive Director of Search & Evaluation for RLT at Novartis.
In this role, he advised the Oncology Leadership Team on emerging scientific and commercial trends in radioligand therapies, led evaluations of external partnership and pipeline opportunities, and played a key role in several strategic licensing and acquisition initiatives.
Before his tenure at Novartis, Dr. Reichen held the position of Strategy Lead at Advanced Accelerator Applications, a Novartis company focused on nuclear medicine. There, he guided major strategic efforts, including PET imaging strategies and comprehensive platform reviews for radioligand therapy.
Earlier in his career, he worked at Bayer Business Consulting, where he advised senior leadership on R&D productivity enhancements, business development and licensing integration, and digital transformation across Bayer’s global pharmaceutical operations.
Dr. Reichen holds a Ph.D. in Biochemical Engineering from University College London (UCL), a M.Sc. in Mechanical Engineering from ETH Zurich, and an MBA from the University of St. Gallen (HSG). His appointment strengthens Ratio’s strategic capabilities as it advances its innovative radiopharmaceutical pipeline.
